NEW YORK (GenomeWeb News) – Myriad Genetics reported after the close of the market on Monday that its third-quarter revenues increased 42 percent, driven by a sharp uptick in molecular diagnostics sales.

The Salt Lake City-based firm generated revenues of $87.5 million for the three-month period ended Mar. 31, compared to $61.8 million for the first quarter of 2008. Its molecular diagnostics sales were $86.5 million, up from $59 million in Q1 2008, while its research and other revenue fell to just under $1 million from $2.7 million the year before.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.